Country Garden International: "Buy" rating given to Shen Wei Pharmaceuticals (02877.HK) with a target price of 10.04 Hong Kong dollars.

According to the Wisdom Finance and Economics APP, Guoyuan International released a research report stating that Shenwei Pharmaceutical (02877.HK) has made smooth progress in the research and development of traditional Chinese medicine, and its core product Selotong Capsules (an innovative Chinese medicine for vascular dementia) has completed Phase III clinical trials. It is expected to be approved in 2026 and listed in 2027. Currently, revenue and gross profit margins are under pressure due to the impact of centralized procurement. However, with the launch of new drugs in the future, the product structure will be optimized, and performance is expected to recover and grow. The company is given a "buy" rating with a target price of HK$10.04 per share.